Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial

医学 威尼斯人 内科学 慢性淋巴细胞白血病 人口 耐火材料(行星科学) 胃肠病学 白血病 苯达莫司汀 微小残留病 活检 肿瘤科 天体生物学 环境卫生 物理
作者
Stephan Stilgenbauer,Barbara Eichhorst,Johannes Schetelig,Peter Hillmen,John F. Seymour,Steven Coutré,Wojciech Jurczak,Stephen P. Mulligan,Anna Schuh,Sarit Assouline,Clemens‐Martin Wendtner,Andrew W. Roberts,Matthew S. Davids,Johannes Bloehdorn,Talha Munir,Sebastian Böttcher,Lang Zhou,Ahmed Hamed Salem,Monali Desai,Brenda Chyla
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:36 (19): 1973-1980 被引量:305
标识
DOI:10.1200/jco.2017.76.6840
摘要

Purpose Venetoclax is an orally bioavailable B-cell lymphoma 2 inhibitor. US Food and Drug Administration and European Medicines Agency approval for patients with 17p deleted relapsed/refractory chronic lymphocytic leukemia [del(17p) CLL] was based on results from 107 patients. An additional 51 patients were enrolled in a safety expansion cohort. Extended analysis of all enrolled patients, including the effect of minimal residual disease (MRD) negativity on outcome, is now reported. Patients and Methods Overall, 158 patients with relapsed/refractory or previously untreated (n = 5) del(17p) CLL received venetoclax 400 mg per day after an initial dose ramp up. Responses were based on 2008 International Workshop on Chronic Lymphocytic Leukemia criteria, with monthly physical exams and blood counts. Computed tomography scan was mandatory at week 36, after which assessment made was by clinical evaluation. Marrow biopsy was performed when complete remission was suspected. MRD was assessed by flow cytometry. Results Patients had a median of two prior therapies (range, zero to 10 therapies), 71% had TP53 mutation, and 48% had nodes that were ≥ 5 cm. Median time on venetoclax was 23.1 months (range, 0 to 44.2 months) and median time on study was 26.6 months (range, 0 to 44.2 months). For all patients, investigator-assessed objective response rate was 77% (122 of 158 patients; 20% complete remission) and estimated progression-free survival at 24 months was 54% (95% CI, 45% to 62%). For 16 patients who received prior kinase inhibitors, objective response rate was 63% (10 of 16 patients) and 24-month progression-free survival estimate was 50% (95% CI, 25% to 71%). By intent-to-treat analysis, 48 (30%) of 158 patients achieved MRD below the cutoff of 10 −4 in blood. Common grade 3 and 4 adverse events were hematologic and managed with supportive care and/or dose adjustments. Conclusion Venetoclax achieves durable responses and was well tolerated in patients with del(17p) CLL. A high rate of blood MRD < 10 −4 was achieved in this high-risk population.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhangyaoyang完成签到,获得积分10
刚刚
合适的尔冬完成签到 ,获得积分10
1秒前
esxl完成签到,获得积分20
1秒前
hunniee完成签到,获得积分10
1秒前
默默完成签到,获得积分10
2秒前
别云间发布了新的文献求助10
4秒前
4秒前
5秒前
飞翔的完成签到,获得积分10
5秒前
酷波er的应助被美满的书包采纳,获得30
6秒前
布鲁斯李完成签到,获得积分10
7秒前
酷波er的应助被马里奥采纳,获得10
7秒前
7秒前
syvshc的应助被Lennon采纳,获得10
8秒前
学术laji完成签到 ,获得积分10
8秒前
leicaixia完成签到 ,获得积分10
8秒前
超级无敌完成签到,获得积分10
9秒前
丽达发布了新的文献求助10
9秒前
秋秋完成签到,获得积分10
9秒前
徐臣年完成签到,获得积分10
9秒前
烨Yang发布了新的文献求助10
10秒前
领导范儿的应助被Taviana采纳,获得20
11秒前
11秒前
sissiarno的应助被吼吼采纳,获得200
12秒前
海宁发布了新的文献求助10
12秒前
xigua123完成签到,获得积分10
13秒前
13秒前
科研通AI6.4的应助被Log采纳,获得10
13秒前
暴躁的飞风完成签到 ,获得积分10
14秒前
15秒前
16秒前
16秒前
愉快的真发布了新的文献求助10
17秒前
wu完成签到,获得积分10
17秒前
顾矜的应助被要减肥采纳,获得10
18秒前
高贵的晓啸完成签到,获得积分10
18秒前
qq星发布了新的文献求助10
18秒前
SciGPT的应助被常常嘻嘻采纳,获得10
19秒前
19秒前
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190724
求助须知:如何正确求助?哪些是违规求助? 9577784
关于积分的说明 21855018
捐赠科研通 7789883
什么是DOI,文献DOI怎么找? 3436455
关于科研通互助平台的介绍 2560308
邀请新用户注册赠送积分活动 2483172